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Neurostimulation has been used in pain management
for a long time. Several neuromodulatory surgical tech-
niques were developed to manage headaches unrespon-
sive to medical treatment, in particular for preventive
treatment. Recently, novel non invasive neurostimulation
approaches have been used successfully for different
forms of headache: they represent a promising opportu-
nity in headache management useful for acute and pre-
ventive treatment of migraine. Among the different non
invasive approaches, transcutaneous supraorbital electro-
stimulation device (Cefaly), transcutaneous magnetic sti-
mulation (TMS), transcranial electrical stimulation
(t DCS), and non-invasive vagus nerve stimulation
device (n VNS) have shown efficacy in a consistent
number of pilot studies (lack of placebo condition).
Vagus Nerve Stimulation (VNS) was a well known surgi-
cal procedure approved for treatment of refractory epi-
lepsy and depression, with a peripheral mechanism of
action. It has been used in selected intractable migraine
cases if associated with comorbid depression, with pro-
mising results. A hand-held patient controlled non-inva-
sive vagus nerve stimulation device (Gammacore) has
been developed to treat migraine attack and has contribu-
ted to an easier treatment of migraine episodes. Goadsby
et al reported significant results from treatment of
migraine attacks by non-invasive transcutaneous vagal
nerve stimulation in a population of 30 patients with a
2-hour pain-free rate of 22%. In our open-label, single
arm, multiple attack, 27 patients, 18-65 years old, with a
diagnosis of migraine without aura according to the IHS
beta 2013 classification, with a high frequency, were
enrolled and participated in the study with 112 attacks
treated. Treatment consisted of one stimulation, 90-sec-
ond dose, delivered to the right cervical branch of the
vagus nerve. In forty-four attacks (39.2%) 9 resolved within
30 minutes; 50 attacks (44.6%) did not resolve in the first
2 hours, so patients used rescue medication; in 18 attacks
(16.2%) there was no complete resolution of pain, but a
significant relief in the first 2 hours (40% in the VAS scale)
and patients did not use any rescue medication. No
adverse events were recorded, the therapy was well toler-
ated. Non-invasive vagus nerve stimulation (nVNS) offers
a novel approach to acute migraine attack. For patients
with high frequency of migraine attacks, nVNS may repre-
sent a suitable tool to decrease the risk of medication
overuse. The variety of non-invasive neuromodulatory
approaches has opened new strategies for treatment of
patients suffering from drug-refractory forms of headache.
Randomized sham controlled studies and larger and multi-
centre trials are needed in order to determine the optimal
dosage and to clarify the mode of action.
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